Latest Daily News

Latest News

June 4, 2017

Data from two phase II studies, the CheckMate 204 trial and the Anti-PD1 Brain Collaboration trial, lend support to combined use of nivolumab and ipilimumab to yield responses in melanoma that has metastasized to the brain.

Read more

June 3, 2017

Although patients have benefited from the expansion of options, questions have arisen about how to select optimal treatment, such as whether to recommend lymph node dissection or immunotherapy compared with targeted therapy.

Read more
May 25, 2017

The 3 mg/kg dose is considered the “standard” dose of ipilimumab, however, there has continued to be debate in the field about the most appropriate dose of ipilimumab, and clinical trials have continued to investigate the 10 mg/kg dose.

Read more
May 25, 2017

Rodabe N. Amaria, MD, answers "In BRAF-mutant melanoma, what regimen should be used as first-line therapy in advanced disease?"

Read more
May 25, 2017

Exploring the benefit the of ipilimumab in the second-line setting for metastatic melanoma.

Read more

May 25, 2017

The 2011 ASCO Annual Meeting Plenary Session ushered in a renaissance for melanoma therapy with the promise of targeted therapy. Results of the BRIM-3 trial marked the beginning of the end of cytotoxic chemotherapy for melanoma.

Read more

June 7, 2016

Treatment with binimetinib improved response rates and significantly prolonged progression-free survival compared with dacarbazine for patients with cutaneous melanoma with an NRAS mutation in the open-label, prospective phase III NEMO trial.

Read more
June 7, 2016

Melanoma experts addressed how treatment is navigated in clinical practice and how risks and challenges may be addressed.

Read more
June 7, 2016

Updated results from CheckMate 067 show that with a minimum of 18 months follow-up the combination of nivolumab plus ipilimumab is still significantly superior compared with ipilimumab alone for patient with advanced melanoma.

Read more
June 7, 2016

Three KEYNOTE studies on pembrolizumab in metastatic melanoma provide insights into its long-term efficacy, its efficacy versus ipilimumab and its efficacy in combination with ipilimumab. What are the clues that hint at a cure for some patients with stage IV disease? 

Read more

May 26, 2016

Are we “putting the cart before the horse” by adding dual immunotherapy agents in study designs when we haven't defined and identified predictive markers to select patient populations to test immunotherapy modalities?

Read more

May 26, 2016

Physicians weigh-in on how the treatment landscape of metastatic melanoma has evolved since MDX010-20 and CA184-024 were presented at the ASCO Annual Meeting.

Read more

May 26, 2016

Dr. James W. Jakub and Dr. Svetomir Markovic review the criteria for performing sentinel lymph node biopsy in patients with melanoma.  

Read more
May 30, 2015

The combination of nivolumab and ipilimumab significantly increased PFS in patients with advanced melanoma compared with ipilimumab alone, according to a randomized, double-blind, phase III trial. AEs were increased with the combination. The high cost of the drugs was also highlighted.

Read more
May 30, 2015

Performing a complete lymph node dissection after identifying micrometastases in the sentinel lymph nodes does not improve survival outcomes for patients with melanoma, according to results of a randomized, phase III, noninferiority trial conducted in Germany.

Read more

May 30, 2015

According to results of a new phase III trial, oral nicotinamide significantly reduced the formation of new nonmelanoma skin cancers compared with placebo in high-risk patients and was well tolerated.

Read more
May 31, 2015

Plans were announced Monday for ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) study and the National Cancer Institute (NCI)-MATCH: Molecular Analysis for Therapy Choice trial (EAY131), two clinical studies which aim to expand the boundaries of precision medicine.

Read more